China-based Kind Pharmaceutical has raised over RMB 400 million in Series C funding led by CGE Healthcare, supporting clinical development of oral small molecule AND017 for chronic kidney disease (CKD)-induced anaemia. The company founded in 2014 advances AND017 into a Phase III registrational trial following successful multinational Phase II studies with parallel Phase II trials ongoing in sickle cell disease (SCD) and myelodysplastic syndromes (MDS). Second lead asset AND019 is a third-generation selective estrogen receptor degrader in Phase I development for breast cancer, with its novel chemical structure inducing protein self-degradation.

The financing accelerates global clinical programmes for weekly oral AND017, demonstrating compliance advantages over injectable erythropoiesis stimulating agents and safety benefits versus HIF-PH inhibitors in renal anaemia, which affects the majority of CKD patients. Investors highlighted the potential best-in-class profile addressing unmet needs in anaemia management across multiple indications. Kind's pipeline includes additional small molecules and antibody drug conjugates (ADCs) in pre-clinical development.

PharmCube's MedAlpha® database shows that Kind's cumulative funding exceeds USD 140 million, including a 2019 Series A and a 2021 Series B. Click here to request a free trial for MedAlpha®.